Back to Search
Start Over
All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis
- Source :
- Respiratory Investigation; September 2015, Vol. 53 Issue: 5 p232-241, 10p
- Publication Year :
- 2015
-
Abstract
- Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease with a median survival of 2–5 years and limited treatment options. In 2008, pirfenidone became the first drug to be approved for IPF treatment in Japan. The aim of this study was to assess the safety of pirfenidone for IPF treatment in a clinical setting.
Details
- Language :
- English
- ISSN :
- 22125345
- Volume :
- 53
- Issue :
- 5
- Database :
- Supplemental Index
- Journal :
- Respiratory Investigation
- Publication Type :
- Periodical
- Accession number :
- ejs36339318
- Full Text :
- https://doi.org/10.1016/j.resinv.2015.06.001